CBT profiles of cabozantinib approved for advanced renal cell carcinomas

被引：12
|
作者：
Wang, Xiangdong [1 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Inst Clin Sci, Shanghai Inst Clin Bioinformat, Shanghai, Peoples R China
来源：
CELL BIOLOGY AND TOXICOLOGY | 2016年 / 32卷 / 04期
关键词：
KINASE; INHIBITORS; MEDICINE; GROWTH;
D O I：
10.1007/s10565-016-9349-6
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：259 / 261
页数：3
相关论文
共 50 条
  • [31] New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma
    Naoun, Natacha
    Vano, Yann-Alexandre
    BULLETIN DU CANCER, 2021, 108 (11) : 991 - 993
  • [32] Advanced Renal Cell Carcinoma Cabozantinib plus Nivolumab becomes Treatment Option of the Future
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (12)
  • [33] Advanced Renal Cell Carcinoma Cabozantinib Monotherapy is the Second-line Therapy Standard
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (11) : 638 - 639
  • [34] Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
    Tsai, Y-C.
    Li, J-R.
    Su, P. J.
    Su, Y-L.
    Chung, H-J.
    Li, C-C.
    Huang, C-P.
    Guo, J-C.
    Chen, C-S.
    Wang, E.
    Perrot, V.
    Chang, Y. H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1487 - S1488
  • [35] US Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
    Singh, Harpreet
    Brave, Michael
    Beaver, Julia A.
    Cheng, Joyce
    Tang, Shenghui
    Zahalka, Eias
    Palmby, Todd R.
    Venugopal, Rajesh
    Song, Pengfei
    Liu, Qi
    Liu, Chao
    Yu, Jingyu
    Chen, Xiao Hong
    Wang, Xing
    Wang, Yaning
    Kluetz, Paul G.
    Daniels, Selena R.
    Papadopoulos, Elektra J.
    Sridhara, Rajeshwari
    Mckee, Amy E.
    Ibrahim, Amna
    Kim, Geoffrey
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (02) : 330 - 335
  • [36] Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
    Santhosh, A.
    Baskarane, H.
    Batra, A.
    Sahoo, R. K.
    Sharma, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1563 - S1563
  • [37] MANAGEMENT OF ADVERSE EVENTS ASSOCIATED WITH CABOZANTINIB PLUS NIVOLUMAB IN ADVANCED RENAL CELL CARCINOMA
    Seery, Virginia
    Andresen, Diane
    Martone, Brenda
    Lee-Ramos, Steven
    Hall, Tasha
    Virdee, Kiran
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [38] Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
    Grassi, Paolo
    Verzoni, Elena
    Ratta, Raffaele
    Mennitto, Alessia
    de Braud, Filippo
    Procopio, Giuseppe
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 2167 - 2172
  • [39] Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma
    不详
    EUROPEAN UROLOGY, 2021, 80 (02) : 256 - 257
  • [40] Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
    Chanza, Nieves Martinez
    Xie, Wanling
    Bilen, Mehrnet Asim
    Dzimitrowicz, Hannah
    Burkart, Jarred
    Geynisman, Daniel M.
    Balakrishnan, Archana
    Bowman, I. Alex
    Jain, Rohit
    Stadler, Walter
    Zakharia, Yousef
    Narayan, Vivek
    Beuselinck, Benoit
    McKay, Rana R.
    Tripathi, Abhishek
    Pachynski, Russell
    Hahn, Andrew W.
    Hsu, JoAnn
    Shah, Sumit A.
    Lam, Elaine T.
    Rose, Tracy L.
    Mega, Anthony E.
    Vogelzang, Nicholas
    Harrison, Michael R.
    Mortazavi, Amir
    Plimack, Elizabeth R.
    Vaishampayan, Ulka
    Hammers, Hans
    George, Saby
    Haas, Naomi
    Agarwal, Neeraj
    Pal, Sumanta K.
    Srinivas, Sandy
    Carneiro, Benedito A.
    Heng, Daniel Y. C.
    Bosse, Dominick
    Choueiri, Toni K.
    Harshman, Lauren C.
    LANCET ONCOLOGY, 2019, 20 (04): : 581 - 590
12345